MEMORANDUM FOR: Science Writers and Editors on the Journal Press List: HER-2 Gene Expression in Lymph Node Metastases Versus the Primary Breast Tumor: Implications for Treatment Failure

2001 ◽  
Vol 93 (15) ◽  
pp. 1117-1117
Author(s):  
K. Arnold ◽  
D. Eckstein
Keyword(s):  
Gene Expression ◽  
Lymph Node ◽  
Treatment Failure ◽  
Lymph Node Metastases ◽  
Breast Tumor ◽  
Primary Breast Tumor ◽  
Her 2 ◽  
Node Metastases

scholarly journals Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients

2019 ◽  
Author(s):  
Ilija Vladimir Baroš ◽  
Nataša Tanasković ◽  
Ulrika Pellas ◽  
Živka Eri ◽  
Ljiljana Tadić Latinović ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Axillary Lymph Node ◽  
Breast Tumor ◽  
Primary Breast Tumor ◽  
Her2 Status ◽  
Axillary Lymph ◽  
Axillary Lymph Node Metastases ◽  
Node Metastases ◽  
Her2 Heterogeneity

Determination of human epidermal growth factor receptor 2 (HER2) status is important for adequate treatment of breast cancer (BC) patients. The novel HER2 gene protein assay (GPA) is particularly convenient, as it allows the simultaneous assessment of HER2 protein expression and gene amplification at individual cell level. Here we investigated the frequency of internodal HER2 heterogeneity in axillary lymph node macrometastases of BC patients and compared HER2 status between primary breast tumor and its metastases. We included a total of 41 female patients operated between 2014 and 2015 for primary BC with axillary lymph node macrometastases. Representative paraffin blocks of metastatic lymph nodes were sectioned and the slides were stained using the GPA in 38 BC cases. GPA results were assessed according to the ASCO/CAP 2013 criteria. We analyzed 12586 individual tumor cells, 120 cells per section of each metastatic lymph node. HER2 status differed between the primary tumor and its metastases in 5/38 cases (13.2%). In patients with at least two metastatic nodes, the HER2 status of lymph node metastases was only slightly different in 4/23 cases (17.4%). Our results indicate rare but substantial differences in HER2 status between primary breast tumor and its axillary lymph node metastases that may direct the choice and outcomes of targeted therapy in BC patients. The impact of the rare and subtle internodal HER2 heterogeneity evidenced in this study remains uncertain. Determining the HER2 status of lymph node metastases in BC seems to be rational, but assessing a limited number of metastatic nodes may be sufficient.

scholarly journals Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis

Tumor Biology ◽  
2017 ◽  
Vol 39 (8) ◽  
pp. 101042831769836 ◽  
Author(s):  
Fereshteh Ahmadinejad ◽  
Seyed Javad Mowla ◽  
Mohammad-Amin Honardoost ◽  
Mostafa Gholami Arjenaki ◽  
Mohammad Moazeni-Bistgani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
In Silico ◽  
Breast Tumors ◽  
Normal Tissues ◽  
Node Metastases ◽  
Lower Expression

Breast cancer is considered as the most prevalent malignancy in women worldwide. Despite emergence of several prognosticators for better management of patients, there are still limitations for their clinical application due to the complexity of breast tumors, and therefore, new biomarkers for better prognosis of clinical outcomes would be of the great essence. MicroRNAs are highly conserved small non-coding regulatory RNAs involved in post-transcriptional regulating of gene expression during different cellular mechanisms. Accumulating studies suggest that miR-218 plays a multifunctional role in various cancer types and different stages. Here, to address prognostic significance of miR-218 in breast cancer, we investigate the expression profile of miR-218 and B-cell-specific Moloney murine leukemia virus integration site 1 ( BMI1) gene, as one of the putative targets of miR-218, in 33 paired breast tumors and their adjacent normal tissues with respect to the clinicopathological features of patients using quantitative real-time polymerase chain reaction. The correlation of both miR-218 and BMI1 gene expression with overall survival of breast cancer patients was also examined recruiting OncoLNC data portal. Finally, to better understand biological function of miR-218 in breast cancer, we performed in silico Gene Ontology and signaling pathway enrichment analysis on miR-218 targetome. According to our data, significant elevation of the expression of miR-218 and downregulation of BMI1 were observed in clinical breast cancer specimens compared with normal tissues ( p < 0.0001). The lower expression of miR-218 was associated with lymph node metastases, higher grades, and poorer prognosis (logrank p = 0.00988), whereas no significant difference in overall survival was observed between patients with higher and lower expression of BMI1 (logrank p = 0.254). These findings suggest that miR-218 expression profiling might be clinically applicable as a prognostic biomarker in breast cancer. In addition, our in silico enrichment analyses revealed that the association of miR-218 expression with breast cancer prognosis might be through its involvement in endocytosis and gap junction biological pathways.

Cytokeratin 7 negative invasive breast carcinoma: clinicopathological and immunohistochemical analysis of 14 cases with clinical follow-up

2015 ◽  
Vol 68 (6) ◽  
pp. 484-487 ◽  
Author(s):  
Neda A Moatamed ◽  
Annie Wu ◽  
Khaled Sarah ◽  
Sophia K Apple
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Proliferation Index ◽  
Axillary Lymph ◽  
Cytokeratin 7 ◽  
Ki 67 ◽  
Her 2 ◽  
Node Metastases ◽  
Work Up

Cytokeratin 7 (CK 7) negative breast tumours are reported to occur rarely. We studied 14 CK 7 negative cases of primary invasive ductal carcinoma (IDC) detected during sentinel lymph node metastases work-up and immunohistochemistry panel in the work-up of metastatic carcinoma of unknown origin. Axillary lymph node metastases were present in seven patients (50%). Oestrogen receptor (ER) was strongly positive in all cases: progesterone receptor in 78%, Her-2/neu in 7% and high proliferation index with Ki-67 >20% was seen in 71% of the cases.Metastatic and/or recurrence were found in 8 of 14 patients (57%) with the mean clinical follow-up of 55 months. Metastatic sites include multiple bones, brain, spinal cord, liver, pancreas, ovary, lung, lymph node other than ipsilateral axillary and skin. 12 of 14 patients received adjuvant chemotherapy. All 14 patients received hormonal therapy and radiation therapy. Morphologically, IDC with neuroendocrine features was noted in 57%. Synaptophysin stain was positive in 57% and chromogranin was positive in 21% of the cases. In conclusion, these CK 7 negative breast carcinomas were ER positive, mostly Her-2/neu negative, had high Ki-67 and frequently showed neuroendocrine differentiation. More than half of these cases had a poor outcome.

Sign in / Sign up

Export Citation Format

Share Document